Chief Executive Officer and Co-Founder, RecovryAI
Appears in 1 story
Leading RecovryAI through FDA regulatory process
The FDA has cleared more than 1,250 artificial intelligence-enabled medical devices — nearly all narrow systems that read scans or flag anomalies without talking to patients. On March 3, 2026, RecovryAI announced that its Virtual Care Assistants were granted Breakthrough Device Designation, the first patient-facing generative large language model product to enter the FDA's accelerated review pipeline.
Updated May 30
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
